AU2018338184B2 - Long-acting co-agonists of the glucagon and GLP-1 receptors - Google Patents

Long-acting co-agonists of the glucagon and GLP-1 receptors Download PDF

Info

Publication number
AU2018338184B2
AU2018338184B2 AU2018338184A AU2018338184A AU2018338184B2 AU 2018338184 B2 AU2018338184 B2 AU 2018338184B2 AU 2018338184 A AU2018338184 A AU 2018338184A AU 2018338184 A AU2018338184 A AU 2018338184A AU 2018338184 B2 AU2018338184 B2 AU 2018338184B2
Authority
AU
Australia
Prior art keywords
seq
xaa
misc
feature
conjugated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018338184A
Other languages
English (en)
Other versions
AU2018338184A1 (en
Inventor
Elisabetta Bianchi
Qiaolin Deng
Chunhui HUANG
Federica Orvieto
Anandan Palani
Yuping Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of AU2018338184A1 publication Critical patent/AU2018338184A1/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Amend patent request/document other than specification (104) Assignors: MERCK SHARP & DOHME CORP.
Application granted granted Critical
Publication of AU2018338184B2 publication Critical patent/AU2018338184B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2018338184A 2017-09-25 2018-09-21 Long-acting co-agonists of the glucagon and GLP-1 receptors Ceased AU2018338184B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762562674P 2017-09-25 2017-09-25
US62/562,674 2017-09-25
PCT/US2018/052124 WO2019060660A1 (en) 2017-09-25 2018-09-21 CO-AGONISTS WITH EXTENDED ACTION OF GLUCAGON AND GLP-1 RECEPTORS

Publications (2)

Publication Number Publication Date
AU2018338184A1 AU2018338184A1 (en) 2020-03-12
AU2018338184B2 true AU2018338184B2 (en) 2023-04-13

Family

ID=65810991

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018338184A Ceased AU2018338184B2 (en) 2017-09-25 2018-09-21 Long-acting co-agonists of the glucagon and GLP-1 receptors

Country Status (11)

Country Link
US (1) US11566057B2 (enExample)
EP (1) EP3700550A4 (enExample)
JP (3) JP2020535138A (enExample)
KR (1) KR102505628B1 (enExample)
CN (1) CN111132690A (enExample)
AU (1) AU2018338184B2 (enExample)
BR (1) BR112020005841A8 (enExample)
CA (2) CA3220650A1 (enExample)
MA (1) MA50474A (enExample)
MX (1) MX2020003217A (enExample)
WO (1) WO2019060660A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022004872A (es) * 2019-10-22 2022-05-13 Nuritas Ltd Tratamiento de enfermedad de higado graso no alcoholico.
EP3842449A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled olefin co-agonists of the glucagon and glp-1 receptors
EP3842061A1 (en) 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled triazole co-agonists of the glucagon and glp-1 receptors
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
US12122817B2 (en) * 2020-09-22 2024-10-22 Serpentide Inc. Long-lasting GLP1 analogue drug for type-2 diabetes
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR20240043778A (ko) * 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN117586373A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效双激动剂化合物
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
EP4724472A2 (en) * 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
GB0308801D0 (en) * 2003-04-16 2003-05-21 Celltech R&D Ltd Chemical compounds
EP1891105B1 (en) 2005-06-13 2012-04-11 Imperial Innovations Limited Oxyntomodulin analogues and their effects on feeding behaviour
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
CN103857408B (zh) 2011-06-22 2017-04-12 印第安那大学科技研究公司 胰高血糖素/glp‑1受体协同激动剂
JP6184404B2 (ja) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプターコアゴニスト
JP6581656B2 (ja) * 2014-10-24 2019-09-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． グルカゴンおよびｇｌｐ−１受容体のコアゴニスト
EP3430033A4 (en) 2016-03-18 2019-11-20 Merck Sharp & Dohme Corp. CONJUGATES OF INSULIN-INCRETIN

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017074798A2 (en) * 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Long-acting co-agonists of the glucagon and glp-1 receptors

Also Published As

Publication number Publication date
JP2020535138A (ja) 2020-12-03
RU2020114220A3 (enExample) 2021-12-28
WO2019060660A1 (en) 2019-03-28
JP2023071869A (ja) 2023-05-23
MX2020003217A (es) 2020-07-29
RU2020114220A (ru) 2021-10-27
US11566057B2 (en) 2023-01-31
EP3700550A4 (en) 2022-02-23
EP3700550A1 (en) 2020-09-02
KR20200057059A (ko) 2020-05-25
CA3076496A1 (en) 2019-03-28
KR102505628B1 (ko) 2023-03-02
JP2023171744A (ja) 2023-12-05
CA3220650A1 (en) 2019-03-28
US20200270325A1 (en) 2020-08-27
BR112020005841A2 (pt) 2020-11-17
CN111132690A (zh) 2020-05-08
BR112020005841A8 (pt) 2023-04-11
MA50474A (fr) 2020-09-02
AU2018338184A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
US11566057B2 (en) Long-acting co-agonists of the glucagon and GLP-1 receptors
CN105307672B (zh) 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂
US11773150B2 (en) Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
CN114349828A (zh) Glp-1/胰高血糖素受体双重激动剂及其应用
CN115298207A (zh) Gip/glp1共激动剂化合物
US10793615B2 (en) Long-acting co-agonists of the glucagon and GLP-1 receptors
US20190175744A1 (en) Insulin-incretin conjugates
JP2020531442A (ja) アシル化オキシントモジュリンペプチド類似体
AU2020412677A1 (en) Stapled triazole co-agonists of the glucagon and GLP-1 receptors
CN112608378A (zh) 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用
RU2779314C2 (ru) Коагонисты рецепторов глюкагона и glp-1 длительного действия
US20230105982A1 (en) Insulin-incretin conjugates
AU2020415355A1 (en) Stapled lactam co-agonists of the glucagon and GLP-1 receptors
US20230270825A1 (en) Stapled olefin co-agonists of the glucagon and glp-1 receptors

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired